Literature DB >> 20452720

Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption.

Tiancheng Liu1, Lisa Y Wu, Clifford E Berkman.   

Abstract

Prostate-specific membrane antigen (PSMA), an established enzyme-biomarker for prostate cancer, has attracted considerable attention as a target for imaging and therapeutic applications. We aimed to determine the effects of PSMA-targeted photodynamic therapy (PDT) on cytoskeletal networks in prostate cancer cells. PSMA-targeted PDT resulted in rapid disruption of microtubules (alpha-/beta-tubulin), microfilaments (actin), and intermediate filaments (cytokeratin 8/18) in the cytoplasm of LNCaP cells. The collapse of cytoplasmic microtubules and the later nuclear translocation of alpha-/beta-tubulin were the most dramatic alternation. It is likely that these early changes of cytoskeletal networks are partly involved in the initiation of cell death. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20452720      PMCID： PMC3201799          DOI： 10.1016/j.canlet.2010.04.003

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  44 in total

1.  Serum levels of PSMA.

Authors:  G P Murphy; S Su; J Jarisch; G M Kenny
Journal:  Prostate       Date:  2000-03-01       Impact factor: 4.104

2.  Caspase-mediated cleavage of cytoskeletal actin plays a positive role in the process of morphological apoptosis.

Authors:  T Mashima; M Naito; T Tsuruo
Journal:  Oncogene       Date:  1999-04-15       Impact factor: 9.867

Review 3.  Targeted photodynamic therapy via receptor mediated delivery systems.

Authors:  Wesley M Sharman; Johan E van Lier; Cynthia M Allen
Journal:  Adv Drug Deliv Rev       Date:  2004-01-13       Impact factor: 15.470

Review 4.  Dual roles of intermediate filaments in apoptosis.

Authors:  Normand Marceau; Bert Schutte; Stéphane Gilbert; Anne Loranger; Mieke E R Henfling; Jos L V Broers; Jasmin Mathew; Frans C S Ramaekers
Journal:  Exp Cell Res       Date:  2007-04-11       Impact factor: 3.905

Review 5.  Prostate-specific membrane antigen.

Authors:  W R Fair; R S Israeli; W D Heston
Journal:  Prostate       Date:  1997-07-01       Impact factor: 4.104

6.  Mechanism of colon cancer cell apoptosis mediated by pyropheophorbide-a methylester photosensitization.

Authors:  J Y Matroule; C M Carthy; D J Granville; O Jolois; D W Hunt; J Piette
Journal:  Oncogene       Date:  2001-07-05       Impact factor: 9.867

7.  Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in-vivo in human prostate during motexafin lutetium-mediated photodynamic therapy.

Authors:  Timothy C Zhu; Jarod C Finlay; Stephen M Hahn
Journal:  J Photochem Photobiol B       Date:  2004-12-02       Impact factor: 6.252

8.  Optimization of light source parameters in the photodynamic therapy of heterogeneous prostate.

Authors:  Jun Li; Martin D Altschuler; Stephen M Hahn; Timothy C Zhu
Journal:  Phys Med Biol       Date:  2008-07-08       Impact factor: 3.609

9.  Cytoskeleton and apoptosis.

Authors:  Olivia Ndozangue-Touriguine; Jocelyne Hamelin; Jacqueline Bréard
Journal:  Biochem Pharmacol       Date:  2008-04-01       Impact factor: 5.858

10.  Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma.

Authors:  Shona H Lang; Catherine Hyde; Ian N Reid; Ian S Hitchcock; Claire A Hart; A A Gordon Bryden; Jean-Marie Villette; Michael J Stower; Norman J Maitland
Journal:  Prostate       Date:  2002-09-01       Impact factor: 4.104
View more
  20 in total

1.  Spacer length effects on in vitro imaging and surface accessibility of fluorescent inhibitors of prostate specific membrane antigen.

Authors:  Tiancheng Liu; Jessie R Nedrow-Byers; Mark R Hopkins; Clifford E Berkman
Journal:  Bioorg Med Chem Lett       Date:  2011-10-04       Impact factor: 2.823

2.  A PSMA-targeted theranostic agent for photodynamic therapy.

Authors:  Ying Chen; Samit Chatterjee; Ala Lisok; Il Minn; Mrudula Pullambhatla; Bryan Wharram; Yuchuan Wang; Jiefu Jin; Zaver M Bhujwalla; Sridhar Nimmagadda; Ronnie C Mease; Martin G Pomper
Journal:  J Photochem Photobiol B       Date:  2016-12-18       Impact factor: 6.252

3.  Biochemical characterization of prostate-specific membrane antigen from canine prostate carcinoma cells.

Authors:  Lisa Y Wu; Jacqueline M Johnson; Jessica K Simmons; Desiree E Mendes; Jonathan J Geruntho; Tiancheng Liu; Wessel P Dirksen; Thomas J Rosol; William C Davis; Clifford E Berkman
Journal:  Prostate       Date:  2014-01-21       Impact factor: 4.104

4.  Targeting prostate cancer cells with a multivalent PSMA inhibitor-guided streptavidin conjugate.

Authors:  Tiancheng Liu; Jessie R Nedrow-Byers; Mark R Hopkins; Lisa Y Wu; Jeonghoon Lee; Peter T A Reilly; Clifford E Berkman
Journal:  Bioorg Med Chem Lett       Date:  2012-04-30       Impact factor: 2.823

5.  Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles.

Authors:  Benjamin B Kasten; Tiancheng Liu; Jessie R Nedrow-Byers; Paul D Benny; Clifford E Berkman
Journal:  Bioorg Med Chem Lett       Date:  2012-11-16       Impact factor: 2.823

6.  A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer.

Authors:  Tanushree Ganguly; Shorouk Dannoon; Mark R Hopkins; Stephanie Murphy; Hendry Cahaya; Joseph E Blecha; Salma Jivan; Christopher R Drake; Cyril Barinka; Ella F Jones; Henry F VanBrocklin; Clifford E Berkman
Journal:  Nucl Med Biol       Date:  2015-06-09       Impact factor: 2.408

7.  Tuning Pharmacokinetics to Improve Tumor Accumulation of a Prostate-Specific Membrane Antigen-Targeted Phototheranostic Agent.

Authors:  Kara M Harmatys; Marta Overchuk; Juan Chen; Lili Ding; Ying Chen; Martin G Pomper; Gang Zheng
Journal:  Bioconjug Chem       Date:  2018-10-29       Impact factor: 4.774

8.  PSMA-targeted SPECT agents: mode of binding effect on in vitro performance.

Authors:  Jessie R Nedrow-Byers; Adam L Moore; Tanushree Ganguly; Mark R Hopkins; Melody D Fulton; Paul D Benny; Clifford E Berkman
Journal:  Prostate       Date:  2012-08-21       Impact factor: 4.104

9.  Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer.

Authors:  Jessie R Nedrow; Joseph D Latoche; Kathryn E Day; Jalpa Modi; Tanushree Ganguly; Dexing Zeng; Brenda F Kurland; Clifford E Berkman; Carolyn J Anderson
Journal:  Mol Imaging Biol       Date:  2016-06       Impact factor: 3.488

10.  Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells.

Authors:  Tiancheng Liu; Lisa Y Wu; Melody D Fulton; Jacqueline M Johnson; Clifford E Berkman
Journal:  Int J Oncol       Date:  2012-10-04       Impact factor: 5.650
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.